Haberler

Abdi İbrahim Opens Turkey’s Largest Biotechnology Drug Manufacturing Facility and Breaks Ground for Two More New Investments

Manufacturing Has Started at AbdiBio

Working for 106 years with the mission of improving the lives it touches, Abdi İbrahim, leader of Turkey’s pharmaceuticals sector, has now inaugurated Turkey’s largest biotechnology drug manufacturing facility AbdiBio. The opening ceremony for the TRY 400 million investment AbdiBio was also the scene of groundbreaking for the Sterile Injectables and Oncology Drugs Manufacturing facilities, which will be launched at an investment of TRY 600 million.

Participating in the opening and groundbreaking ceremonies Abdi İbrahim Board Chairman Nezih Barut, Vice-Chairman Nesrin Barut Esirtgen, Board Member Ahmet Kamil Esirtgen, and Executive Board and Board Member Cenan Esirtgen.

In his speech, Nezih Barut explained that AbdiBio’s biotech drugs would play a role in reducing imports of these products and increasing exports, thus serving as a medicine for the current accounts deficit. He said, “The investment in our Esenyurt manufacturing complex amounts to a total of TRY 2.5 billion. Together with our international investments, our investment figure has reached TRY 3 billion. As a company, we measure our assets by our contribution to the country’s development. In this belief, as we have done so far, we will continue to invest further, produce more, increase the volume of our exports while also increasing our workforce so that we can continue to create added value not only for our company but for our country’s economy.”

Working for 106 years with passion to improve the quality of the lives it touches with its innovative products and services and its bold and pioneering initiatives, Abdi İbrahim has inaugurated its TRY 400 million investment, the biotechnology drugs manufacturing facility AbdiBio with the participation of Abdi İbrahim Board Chairman Nezih Barut, Board Vice-Chairman Nesrin Barut Esirtgen, Board Member Ahmet Kamil Esirtgen, and Executive Board & Board Member Cenan Esirtgen. Built as an indoor area of 13,000 square meters, AbdiBio will be working with the capacity to produce an annual 11 million vials, 9 million syringes, 22 million cartridges and 1 million lyophilized units, earning the distinction of being Turkey’s largest biotechnology drug manufacturing facility.

The opening ceremony for the TRY 400 million investment AbdiBio was also the scene of groundbreaking for the Sterile Injectables and Oncology Drugs Manufacturing facilities, which will be launched at an investment of TRY 600 million.

Nezih Barut: “This is a historical moment for our country and for our sector”

Speaking at the opening ceremony of AbdiBio, Board Chairman Nezih Barut said that as one of Turkey’s oldest industrial corporations, the company’s activities to create added value for the pharmaceuticals sector and Turkey’s economy were ongoing. Expressing his pride in the two new investments, the Sterile Injectables and Oncology Manufacturing Facilities, for which groundbreaking was being undertaken together with the opening of AbdiBio, Barut said, “With our bold and progressive endeavors, our sense of responsibility toward our country and our passion for our work, Abdi İbrahim has always been a company that has constantly raised the bar. We have always believed in the potential of the Turkish pharmaceuticals sector, the strength of our country and the future, constantly contributing to these elements by increasing our investments, which we continue to do. AbdiBio is a monumental reflection of our convictions in this context.

“At AbdiBio, we will be manufacturing at world standards”

Emphasizing that the pharmaceuticals sector both in the world and in Turkey was going through great changes and transformations, Nezih Barut said that biotechnology was at the focal point of all of the change, adding, “Biotechnology methods are steadily becoming more operative in the development of new drugs to combat diseases. AbdiBio echoes the vision of Abdi İbrahim regarding transformation in the drugs sector. This vision will not only enhance our own company’s competitive edge, but also the competitive power of the Turkish pharmaceuticals sector as a whole. This investment will add value to the entire industry.” “According to IQVIA data, Barut continued, “in terms of value, 6 out of 10 drugs in the world and 9 in Turkey are biotechnological. The market share of biotechnology products in the world is 27 percent whereas in Turkey it is 22 percent. In the years ahead, it is expected that the market for biotech drugs will grow beyond other markets. In such an environment, we wanted to be a trailblazer in the biotechnology field as Turkey’s leading pharmaceuticals company. AbdiBio, equipped with the latest technology, is the manifestation of Abdi İbrahim’s determination and ambitions in the area of biotechnology and, with its investment of TRY 400 million, it carries the distinction of being Turkey’s largest biotechnology drugs manufacturing facility. We will be manufacturing at this facility at world standards. From cell banking to the final product, all of the manufacturing processes will be carried out at this factory. We will be manufacturing biotechnology products that will be used in the treatment of cancer, diabetes, rheumatism, central nervous system, eye illnesses, and blood diseases. Besides offering these drugs for use in Turkey, we will export them abroad. At the same time, we will respond to the manufacturing needs of other companies through this facility. All of these activities will play a role in reducing the import of biotechnology products and increasing their export, becoming a medicine for the current accounts deficit, which is one of the most significant issues prevailing in the economy today. The results we will be gleaning from our AbdiBio investment will make an important contribution to the Drug Localization incentive started by our government which we fully support.”

“AbdiBio will be a center of knowhow in biotechnology”

Underlining the fact that there is a scarcity of manpower trained in the area of biotechnology, Nezih Barut said that AbdiBio will be providing an arena for qualified jobs that require meticulously specialized abilities. Pointing out that while incorporating local human resources into its processes, Barut said that the facility will also provide the means of training new specialists and, with the contributions of experts from abroad, the new factory will become a center of knowhow where 250 specialists will be working within two years. Barut continued, “The ideal we dream of in the big picture with this factory is that we contribute to making Turkey a global player in the pharmaceuticals industry and I can say that we have taken a momentous step in this direction. But we can’t be content with only this. Turkey’s ability to take a giant step in pharmaceuticals depends upon its ability to discover new molecules. As Abdi İbrahim, after launching this facility, our focus will be on the discovery of molecules. We want to be pioneers in this as well.” Stressing that Abdi İbrahim’s share in R&D expenditure in the Turkish pharmaceuticals sector was at a level of 16 percent, Barut said that this represented the largest volume of resources allocated to R&D among pharmaceutical companies and continued, “I hope that this and similar investments will carry us to the economic fortitude that will enable us to allocate even more resources to Research and Development. At Abdi İbrahim, we are accustomed to thinking big and running after big targets. Our vision for 2020 is to take our place among the 100 largest pharmaceutical companies in the world. Our investments are continuing uninterruptedly.”  

“The two new facilities for which we are breaking ground will start manufacturing in 2020.”

Commenting that the Sterile Injectables and Oncology Drugs Manufacturing Facility investments total TRY 600 million and will be launched in 2020, Barut said, “Our investment process in the field of Ophthalmology, which is a part of our manufacturing complex, is about to be completed. In this area of manufacturing, representing an investment of TRY 240 million, ophthalmological products, which are largely being imported today, will finally be manufactured in Turkey. In the same way, our Hormonal Drugs Manufacturing branch, representing an investment of TRY 18 million will be in operation sometime this year. Our Esenyurt manufacturing complex investment amounts to a total of TRY 2.5 billion. Together with our international investments, our investment figure has reached TRY 3 billion. “

“The number of our employees will reach 4,500 at the end of 2018.”

Barut explained that as a company based on 100% local capital, they have been leaders in both turnover and on the basis of the volume of boxes for 16 years. He said that besides their facilities in Turkey, they had built and started manufacture in the most modern facilities in the region in Kazakhstan and Algeria, operating in a total of 12 countries under the umbrella of their own organization and exporting products to a total of 50 countries on a broad spectrum, from the EU country of Canada to North Africa and Asia. Nezih Barut stressed that their target for 2018 was to achieve a growth of 32 percent in export and international returns, ending his words by saying: “We love our country and we support it in its struggle against every kind of threat with the power of our production and the employment opportunities we provide. Since the attempted coup of July 15, the number of people we have provided with new jobs has reached 1,175. Abdi İbrahim employs 4,000 people at this time, including in international markets. By the end of 2018, we will bring this figure up to 4,500, maintaining our identity as the company that provides the greatest number of jobs in the Turkish pharmaceuticals sector. Our ambition is to contribute to the development of the industry and more importantly, to pay back our debt to the land that we were born and raised in. As a company, we measure our assets by our contribution to the country’s development. In this belief, as we have done so far, we will continue to invest further, produce more, increase the volume of our exports while also increasing our workforce so that we can continue to create added value not only for our company but for our country’s economy.”
SİTE HARİTASI
BİLGİ TOPLUMU HİZMETLERİ
© 2011-2017 Abdi İbrahim İlaç Sanayi ve Tic A.Ş.
Bu sitede yer alan bilgiler, hekim ve eczacıya danışmanın yerine geçmez. Abdi İbrahim ilaçları ile ilgili her türlü bilgi talebinde bize ulaşabilirsiniz;
Tel: 0212 366 8400
E-Posta: info@abdiibrahim.com.tr